Vol. 5 No. 11 (2025)
Reimbursement Recommendations

Risankizumab (Skyrizi)

decorative image of the issue cover

Published November 4, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Skyrizi be reimbursed by public drug plans for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor if certain conditions are met.
  • Skyrizi should be covered for a similar patient population and in a similar way to other advanced therapies for UC currently reimbursed by public drug plans for the treatment of moderately to severely active UC.
  • Skyrizi should only be reimbursed if it is prescribed by a physician experienced in the diagnosis and management of UC if it is not used in combination with other advanced therapies for UC and if the cost of Skyrizi is reduced so that it does not cost the drug programs more than the least costly relevant advanced therapy reimbursed in this patient population. A patient’s disease must respond to treatment within the first 12 weeks of starting Skyrizi to continue receiving the drug.